Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2006

View Archived Issues

Lipid Sciences files IDE for Plasma Delipidation System-2

Private placement funds to support phase II Reolysin development

Zydus Cadila files IND for antiinflammatory compound ZYI-1

Samaritan initiates new phase IIb for SP-01A in HIV

Positive results from synDNA hepatitis B study

InSite Vision completes debt refinancing to support AzaSite development and filing

Recordati signs agreement with Osmotica for modified-release lercanidipine

sNDA submission for Seroquel in bipolar depression

Cerus files IND for phase I study of CRS-100

New designer antibacterial agents from Rib-X Pharmaceuticals

MBX-037 demonstrates antibacterial potential of DNA polymerase IIIC inhibitors

New agents with activity against HIV reported in patent literature

New agents and strategies for respiratory disorders

Cervical cancer vaccine induces greater response in younger women

Inhaled aztreonam reduces P. aeruginosa in cystic fibrosis patients

NDA submission for telbivudine in chronic hepatitis B

U.S. launch for Increlex

Symadex studied in metastatic breast cancer

KRX-0401 studied in new phase II trial for multiple myeloma

Selective targeting of the immunoproteasome for hematologic malignancies

Nonapprovable letter for Cesamet labeling changes

AZD-2479 for dyslipidemia begins phase I study

Studies reveal antibiotic activity of CSA-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...